Johnson & Johnson MedTech Announces Largest Global Restructuring in a Decade, Transitioning to Business Unit-Led Operating Model

Recently,Johnson & Johnson MedTechIt was announced that, effective January 1, 2026, its global business operations model will be fully transitioned from the current "Regional" system."Business Unit (BU) Leadership"Global operational structure.

This adjustment is not a sudden decision, but a continuation and deepening of the organizational transformation initiated at the beginning of 2024 — at that time, approximately 35,000 MedTech employees had already been integrated into various business units (BUs), marking the first step towards a decentralized, end-to-end operational model. In an internal memo to employees, senior management noted that this restructuring aims to "reduce bureaucratic levels, strengthen accountability and ownership, and enhance institutional responsiveness," with the ultimate goal of "becoming more competitive and creating greater value for customers and patients."

# Why Choose to Restructure at This Time

In recent years, the global medical device industry has been undergoing profound changes — technologies and services such as precision medicine, minimally invasive surgery, digital healthcare, robotics, and interventional devices are rapidly developing, demanding higher responsiveness, faster product iteration, cross-regional collaboration, compliance, and localization. In this environment, the regional operation model of traditional large medical device companies appears cumbersome, slow to react, and resource-dispersed, which is not conducive to rapid innovation and global promotion.

At the same time, Johnson & Johnson also announced that it will spin off its orthopedics business. DePuy Synthes, spinning it off. This portion of the business previously accounted for nearly 30% of its global MedTech revenue. Divesting the orthopedic business allows the company to free up resources and strategic focus, enabling the remaining operations to concentrate more on high-growth, high-barrier fields such as cardiovascular, surgical, vision care, and interventional devices.

Therefore, shifting the overall organizational structure to a BU-led model will help the company accelerate resource focus, enhance specialized operational capabilities, improve product launch and commercialization efficiency, and better adapt to the future medical device industry's demands for speed, efficiency, and flexibility.

# Main Arrangements of the New Architecture

• Starting from 2026, each business unit will be responsible for its global business performance — the entire chain from strategic planning, product development, market promotion to commercial execution will be fully managed by the BU.

• All Commercial leaders will report directly to their respective business units, instead of going through regional headquarters layer by layer.

• Surgery and Electrophysiology & Neurovascular will establish independent regional leadership structures — overseen separately by the President of the Surgery BU and the President of the Electrophysiology & Neurovascular BU.

• The supply chain will be centrally managed, with the original regional supply chain teams integrated into a unified group supply chain department to improve global procurement and distribution efficiency.

• All functional support departments (such as R&D, compliance, quality management, etc.) will be restructured to adapt to the new BU-led operational model.

• Public information shows that this adjustment does not affect the direct job positions of client-facing roles (such as hospital sales and service positions).Moreover, the business in China is temporarily out of the scope of this reorganization and will continue to follow the current regional operation model.

# The Strategic Significance of This Restructuring

For Johnson & Johnson itself

• Improve Operational Efficiency and Response Speed— The BU-led model grants businesses greater autonomy and decision-making flexibility, reduces hierarchy and approval processes, enabling the company to respond more quickly to market changes and clinical needs.

• More centralized and professional resource allocation— Spin off from orthopedics + focus on high-growth sectors (cardiovascular, surgical instruments, vision, interventional, etc.), directing R&D and commercial resources toward fields with greater growth potential and technological sophistication.

• Accelerate Product Innovation and Global Commercialization— Each BU implements closed-loop management from product design to global promotion, which facilitates faster new product launches and global market synergy, enhancing global competitiveness.

For the industry and the market

• Driving the Transformation Trend of Large Medical Device Companies— This move by Johnson & Johnson could set an industry trend, encouraging more established medical device companies to restructure in order to adapt to rapid technological and market changes.

• Enhance the Timeliness and Coverage of Hospitals and Patients Accessing Innovative Devices— BU-led + globally unified advancement may shorten the new product launch cycle, enabling advanced devices and treatment solutions to be promoted globally at a faster pace, enhancing healthcare accessibility.

• Exacerbate changes in the competitive market landscape— In the fields of advanced intervention, digital healthcare, and surgical/operational instruments, centralization, specialization, and rapid response may become new dimensions of competition. Small and medium-sized innovative companies and new entrants will face new challenges and may be integrated or collaborate.

# Summary

Johnson & Johnson Medical Technology's business unit restructuring this time reflects a deep understanding of industry trends, corporate strategy, and future growth potential — it represents not only a change in organizational structure but also the company’s commitment to a "faster, more specialized, and more agile" development pace.

Divesting the orthopedic business, focusing on high-growth sectors, and implementing BU-led management will help the company, driven by innovation and backed by efficiency, to accelerate the transition of medical device products and services from development to clinical use and the market in the coming years, bringing more value to patients worldwide.